| 李国松,危之萍,郭奕利.替格瑞洛对 ST段抬高型心肌梗死病人经皮冠状动脉介入治疗后心肌微循环、心功能、不良心血管事件发生情况的影响[J].安徽医药,2022,26(3):612-616. |
| 替格瑞洛对 ST段抬高型心肌梗死病人经皮冠状动脉介入治疗后心肌微循环、心功能、不良心血管事件发生情况的影响 |
| Effects of tigrilol on myocardial microcirculation, cardiac function and adverse cardiovascular events after PCI in STEMI patients |
| |
| DOI：10.3969/j.issn.1009-6469.2022.03.045 |
| 中文关键词: ST段抬高型心肌梗死 替格瑞洛 经皮冠状动脉介入治疗 心肌微循环 心功能 不良心血管事件 |
| 英文关键词: ST segment elevation myocardial infarction Ticagrelor PCI Myocardial microcirculation Cardiac function Adverse cardiovascular events |
| 基金项目: |
|
| 摘要点击次数: 1020 |
| 全文下载次数: 354 |
| 中文摘要: |
| 目的探讨替格瑞洛对 ST段抬高型心肌梗死( STEMI)病人经皮冠状动脉介入治疗( PCI)后心肌微循环、心功能、不良心血管事件发生情况的影响。方法 2017年 8月至 2018年 7月间在北京大学深圳医院接受治疗的 STEMI病人 112例，按随机数字表法将其分为替格瑞洛组、氯吡格雷组，各 56例。替格瑞洛组接受 PCI术前及术后替格瑞洛干预，氯吡格雷组接受 PCI术前及术后氯吡格雷干预。均持续干预 12个月。对比两组病人的血小板聚集率、心肌微循环参数［造影剂开始灌注时间( AT)、灌注峰值强度( PI)、灌注达峰时间( APT)］、心功能参数［左室射血分数( LVEF)、心脏指数、每搏输出量指数( SVI)］、主要不良心血管事件( MACE)［心源性猝死、非致死性急性再梗死、靶血管再次血运重建］发生情况的差异。结果 PCI术后 24 h、术后 1周，替格瑞洛组血小板聚集率［( 30.26±4.73)%、(27.23±4.23)%］低于氯吡格雷组病人［( 37.11±4.65)%、(32.04±4.81)%］(P<0.05)。术后1周，替格瑞洛组 AT、APT水平［(2.21±0.26)s、(2.63±0.29)s］低于氯吡格雷组［(2.50±0.28)s、(3.20±0.38)s］PI的水平( 6.31±0.73)dB高于氯吡格雷组( 6.01±0.74)dB；LVEF、心脏指数、 SVI水平［( 55.17±6.23)%、(3.52±0.46)L·min?1·m?27.42±6.89)mL/m2］均高于氯吡格雷组［( 52.65±6.59)%、(3.10±0.37)L·min?1·m?2、(51.07±6.33)mL/m2］(均 P<0.05)。 PCI后 30d内，两组病人的 MACE总发生率及心源性猝死、非致死性急性再梗死、靶血管再次血运重建发生率的差异无统计学意义( P>0.05)。结论替格瑞洛在改善 STEMI病人 PCI后心肌微循环、提升心功能方面具有优势，其在减少 MACE发生率方面的作用尚不显著。 |
| 英文摘要: |
| Objective To investigate the effects of tigrilol on myocardial microcirculation, cardiac function and adverse cardiovascular events after PCI in STEMI patients.Methods One hundred and twelve cases of STEMI patients undergoing treatment in PekingUniversity Shenzhen Hospital from August 2017 to July 2018 were assigned into tigrilol group and clopidogrel group by random numbertable method, each with 56 cases. Patients in tigrilol group were treated with tigrilol intervention before and after PCI, while those inclopidogrel group were treated with clopidogrel intervention before and after PCI. Both groups received intervention for 12 months. Acomparison was made between the groups of platelet aggregation rate, myocardial microcirculation parameters [perfusion time of thecontrast agents (AT), peak intensity (PI) and perfusion peak time(APT)], cardiac function parameters [left ventricular ejection fraction(LVEF), cardiac index (CI), stroke volume index (SVI)], and major adverse cardiac events (MACE) [sudden cardiac death, nonfatalacute reinfarction, target vessel revascularization].Results Twenty four hours after PCI and 1 week after PCI, the platelet aggregationrates [(30.26±4.73)%, (27.23±4.23)%] of the ticagrelor group were lower than those of the clopidogrel group [(37.11±4.65)%, (32.04±4.81)%] (P<0.05). One week after operation, the levels of AT and APT [(2.21±0.26) s, (2.63±0.29) s] in the ticagrelor group were lowerthan those in the clopidogrel group [(2.50±0.28) s, (3.20±0.38) s], and the level of PI was higher than that in the clopidogrel group[(6.31±0.73) dB vs. (6.01±0.74)dB]; LVEF, CI, and SVI levels [(55.17±6.23)%, (3.52±0.46)L·min?1·m?2, (57.42±6.89)mL/m2] were higher than those in the clopidogrel group [(52.65±6.59)%, (3.10±0.37)L·min?1 ·m?2, (51.07±6.33)mL/m2] (all P<0.05). Within 30 days after PCI, the total incidence of MACE and the incidences of sudden cardiac death, non-fatal acute reinfarction, and target vessel revascularization were not statistically different between the two groups (P>0.05).Conclusion Tigrilol has advantages in improving myocardialmicrocirculation and cardiac function after PCI in STEMI patients, but its effect on reducing MACE incidence is not significant. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
